Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine.
Ontology highlight
ABSTRACT: The combination of gemcitabine with platinum agents is a widely used chemotherapy regimen for a number of tumour types. Gemcitabine plus cisplatin remains the current therapeutic choice for biliary tract cancer. Gemcitabine is associated with multiple cellular drug resistance mechanisms and other limitations and has thereforelined in use. NUC-1031 (Acelarin) is a phosphorylated form of gemcitabine, protected by the addition of a phosphoramidate moiety, developed to circumvent the key limitations and generate high levels of the cytotoxic metabolite, dFdCTP. The rationale for combination of gemcitabine and cisplatin is determined by in vitro cytotoxicity. This, however, does not offer an explanation of how these drugs lead to cell death. In this study we investigate the mechanism of action f
SUBMITTER: Patel D
PROVIDER: S-EPMC11426158 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA